COMPRATIVE ANTIMICROBIAL EFFICACY EVALUATION OF A NEW PRODUCT ELORES AGAINST MEROPENEM ON GRAM NEGATIVE ISOLATES
Background and objective: Increased resistance of Gram-negative bacteria towards most of the available antibiotics, especially beta-lactam
antibiotics is a prime difficulty for the treatment of infections caused by these pathogens. In view of the fact that there is a continuous increase in the
antibitic resistance and the limited available therapeutic options, we aimed the present work to evaluate the antibiotic susceptibility pattern of 847
isolates towards meropenem and Elores (ceftriaxone+sulbcatam+and adjuvant ethylenediaminetetraacetic acid).
Methods: A total of 1180 clinical samples were collected from patients suspected of bacterial infection between January 2014 to June 2014. These
samples were subjected for bacterial identification. Antibiotic susceptibility testing were carried out according to the recommendations of Clinical
Laboratory Standards Institute (CLSI) guidelines.
Results: Among the samples which showed the presence of bacteria, around 29.04% samples were of sputum followed by urine and blood which
contributed to 21.95% and 12.51%, respectively. Escherichia coli (39.55%) was found to be the most dominant pathogen, followed by Pseudomonas
aeruginosa (19.12%), Klebsiella pneumoniae (12.39%), Proteus mirabilis (8.50%), Klebsiella oxytoca (8.26%), Acinetobacter baumannii (5.31%),
Morganella morganii (3.77%), Serratia marcescens (2.24%). The susceptibility of Elores was comparable with meropenem in some of the organisms,
but Elores displayed higher susceptibility in E. coli, A. baumannii, K. pneumoniae, P. mirabilis, K. oxytoca, M. morganii and S. mercescens which might be
due to presence of metallo-beta lactamases in these isolates.
Conclusion: Overall, the results of this study strongly advocate the equivalance of Elores with meropenem and can be of very effective alternative to
treat against the deadly multi drug resistant Gram-negative bacteria.
Keywords: Elores, Gram-negative bacteria, Nosocomial infections, Antimicrobial Resistance, Susceptibility.
1. Kumar D, Singh AK, Ali MR, Chander Y. Antimicrobial susceptibility profile of extended spectrum ÃŸ-lactamase (ESBL) producing Escherichia coli from various clinical samples. Infect Dis (Auckl) 2014;7:1-8.
2. Hughes AJ, Ariffin N, Huat TL, Abdul Molok H, Hashim S, Sarijo J, et al. Prevalence of nosocomial infection and antibiotic use at a university medical center in Malaysia. Infect Control Hosp Epidemiol 2005;26(1):100-4.
3. Mathur P, Kapil A, Das B, Dhawan B. Prevalence of extended spectrum beta lactamase producing Gram-negative bacteria in a tertiary care hospital. Indian J Med Res 2002;115:153-7.
4. Mohanty S, Kapil A, Das BK, Dhawan B. Antimicrobial resistance profile of nosocomial uropathogens in a tertiary care hospital. Indian J Med Sci 2003;57(4):148-54.
5. Mohanty S, Kapil A, Dhawan B, Das BK. Bacteriological and antimicrobial susceptibility profile of soft tissue infections from Northern India. Indian J Med Sci 2004;58(1):10-5.
6. Ayalew K, Nambiar S, Yasinskaya Y, Jantausch BA. Carbapenems in pediatrics. Ther Drug Monit 2003;25(5):593-9.
7. Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, et al. Comparative review of the carbapenems. Drugs 2007;67(7):1027-52.
8. Brink AJ, Feldman C, Grolman DC, Muckart D, Pretorius J, Richards GA, et al. Appropriate use of the carbapenems. S Afr Med J 2004;94:857-61.
9. Shah D, Narang M. Meropenem. Indian Pediatr 2005;42(5):443-50.
10. Merrem IV. Meropenem for Injection [Package Insert]. Wilmington, DE: AstraZeneca Pharmaceuticals; 2007.
11. Francis RO, Wu F, Della-Latta P, Shi J, Whittier S. Rapid detection of Klebsiella pneumoniae carbapenemase genes in Enterobacteriaceae directly from blood culture bottles by real-time PCR. Am J Clin Pathol 2012;137(4):627-32.
12. Hu F, Chen S, Xu X, Guo Y, Liu Y, Zhu D, et al. Emergence of carbapenem-resistant clinical Enterobacteriaceae isolates from a teaching hospital in Shanghai, China. J Med Microbiol 2012;61:132-6.
13. Gupta E, Mohanty S, Sood S, Dhawan B, Das BK, Kapil A. Emerging resistance to carbapenems in a tertiary care hospital in north India. Indian J Med Res 2006;124(1):95-8.
14. Grundmann H, Livermore DM, Giske CG, Canton R, Rossolini GM, Campos J, et al. Carbapenem-non-susceptible Enterobacteriaceae in Europe: Conclusions from a meeting of national experts. Euro Surveill 2010;15(46):19711.
15. Varaiya A, Kulkarni M, Bhalekar P, Dogra J. Incidence of metallo-beta-lactamase-producing Pseudomonas aeruginosa in diabetes and cancer patients. Indian J Pathol Microbiol 2008;51(2):200-3.
16. Chaudhary M, Payasi A. Antimicrobial susceptibility patterns and molecular characterization of Klebsiella pneumoniae clinical isolates from north Indian patients. Int J Med Med Sci 2013a;46(2):1218-24.
17. Toolkit CR. CDC-Guidance for Control of Carbapenem-resistant Enterobacteriaceae (CRE), 2012. Available from:http://www.cdc.gov/hai/pdfs/cre/cre-guidance-508.pdf.
18. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-third Informational Supplement. Wayne, PA 19087 USA: CLSI Document M100-S23; 2013.
19. Chaudhary M, Payasi A. Rising antimicrobial resistance of Pseudomonas aeruginosa isolated from clinical specimens in India. J Proteomics Bioinform 2013b;6:5-9.
20. Uma Karthika R, Srinivasa Rao R, Sahoo S, Shashikala P, Kanungo R, Jayachandran S, et al. Phenotypic and genotypic assays for detecting the prevalence of metallo-beta-lactamases in clinical isolates of Acinetobacter baumannii from a South Indian tertiary care hospital. J Med Microbiol 2009;58:430-5.
21. Chaudhary M, Sudaroli M, Kumar S, Krishnaraju V. Catering ESBL resistance challenge through strategic combination of ceftriaxone, sulbactam and Ethylenediaminetetra acetic Acid. Int J Drug Dev Res 2012a;4:72-81.
22. Chaudhury M, Kumar S, Payasi A. Role of CSE1034 in E. coli biofilm destruction. J Microb Biochem Technol 2013a;5:54-8.
23. Chaudhury M, Kumar S, Payasi A. A novel approach to combat acquired multiple resistance in E. coli by using EDTA as efflux pump inhibitor. J Microb Biochem Technol 2012b;4(6):126-30.
24. Chaudhury M, Payasi A. Inhibition of metalo beta lactamases by ELORES. J Antimicrob 2013b;128:177-82.
25. Sikka R, Mann JK, Deep, Vashist MG, Chaudhary U, Deep A. Prevalence and antibiotic sensitivity pattern of bacteria isolated from nosocomial infections in a surgical ward. Indian J Clin Pract 2012;22:519-25.
26. Patel J, Bhatt J, Javiya V, Patel K. Anti-microbial susceptibility patterns of Enterobacteriaceae isolated from a tertiary care unit in Gujarat. Internet J Microbiol 2009;6:1-27.
27. Mehta M, Bhardwaj S, Sharma J. Prevalence and antibiotic susceptibility pattern of multi-drug resistant Escherichia coli isolates from urinary tract infection (UTI) patients. Int J Life Sci Pharm Res 2012;2:6-11.
28. Sahu M, Sanjith S, Bhalekar P, Keny D. Waging war against extended spectrum Beta lactamase and metallo beta lactamase producing pathogens- Novel adjuvant antimicrobial agent cse1034- An extended hope. J Clin Diagn Res 2014;8(6):DC20-3.
29. Parveen RM, Harish BN, Parija SC. Emerging carbapenem resistance among nosocomial isolates of Klebsiella pneumoniae in south India. Int J Pharm Bio Sci 2010;1:1-11.
30. Chaudhary M, Payasi A. Clinical, microbial efficacy and tolerability of Elores, a novel antibiotic adjuvant entity in ESBL producing pathogens: Prospective randomized controlled clinical trial. J Pharm Res 2013c;7:275-80.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.